Phase III IMpower130 study of Tecentriq + chemo shows OS gain in NSCLC.- Genentech/Roche.

Genentech/Roche announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that Tecentriq plus chemotherapy helped people live significantly longer compared to chemotherapy alone (median overall survival [OS] = 18.6 versus 13.9 months; hazard ratio [HR] = 0.79; 95 percent CI: 0.64�0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) population.

The Tecentriq-based combination also significantly reduced the risk of disease worsening or death (progression-free survival; PFS) compared to chemotherapy alone (median PFS=7.0 versus 5.5 months; HR=0.64; 95 percent CI: 0.54�0.77; p<0.0001) in the itt-wt population. safety for the tecentriq plus chemotherapy combination appeared consistent with the known safety profile of the individual medicines and no new safety signals were identified with the combination. the data will be presented at the european society for medical oncology esmo 2018 congress.>

Comment: Tecentriq was approved by the FDA in October 2016 to treat metastatic non-small cell lung cancer patients who have disease progression during or following platinum-containing chemotherapy.In September 2017 the European Commission granted a marketing authorisation for Tecentriq as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer after they have been previously treated with chemotherapy regardless of PD-L1 status.